Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results for the third quarter ended September 30, 2007 and operational highlights.

"The third quarter of 2007 marked an important transition for Anadys," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "We elected to focus investment on our two product candidates we believe most likely to create value, ANA598 for hepatitis C virus infection and ANA773 in oncology. Concurrently, we discontinued development of ANA975 and ANA380 and ceased early discovery efforts."

"We decided to focus on ANA598 and ANA773 based on the demonstrated preclinical properties of these compounds and our anticipation of future clinical benefits," continued Dr. Worland. "We are pleased to announce today that our IND to commence clinical investigation of ANA773 has been accepted by the FDA and we look forward to initiating a trial in cancer patients by the end the year. In parallel, we continue to advance ANA598 through IND enabling studies. We believe that our decision to focus investment on these two product candidates will enable us to achieve meaningful clinical milestones in both programs with our existing cash reserves."

Financial Results

In the third quarter, the Company and its collaborator, Novartis, decided to discontinue the development of ANA975, a Phase 1b compound for the treatment of hepatitis C virus (HCV) infection. Also during the third quarter, Novartis and Anadys concluded that no further activities will be pursued under the c
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/22/2014)... ITRA Global, one of the largest ... real estate, has further expanded its global reach with ... Brisbane, Western Australia, reports Mylinda Vick, CCIM, Chairman of ... Global / ACORPP (Australian Corporate Property and Projects) , ... property services to a wide range of clients in ...
(Date:12/19/2014)... December 19, 2014 Bioject Medical ... and manufacturer of needle-free injection technology, today announced ... Immunomic Therapeutics, Inc. (“ITI”) for ITI to use ... its LAMP™ vaccine platform. , In the ... Worldwide license to the Biojector®-2000 that triggers based ...
(Date:12/19/2014)... 2014 BioPlus Specialty Pharmacy ... the promotion of Nick Maroulis, Pharm.D. to the newly ... , In this position, Dr. Maroulis will continue ... the directors of our multi-site pharmacies as the company ... and during that time he has served in many ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... ... Process Optimization Using At-Line Particle Characterization”, will be presented on December 2, 2009. ... the design space and optimize a series of roller compaction runs while varying raw ... ...
... 19 Danish Prince Joachim inaugurated the DONG Energy ... Wednesday, November 18. The facility is one of the ... Genencor,s Accellerase enzymes are used in the plant,s innovative ... of Danisco, was the first to market with commercial ...
... , , BETHESDA, Md., ... innovator in biotechnology for diabetes therapy, and a provider of ... pharmaceutical companies, announced today it closed the previously reported $6.3 ... of its common stock and warrants to purchase up to ...
Cached Biology Technology:Roller Compaction Process Optimization Using At-Line Particle Characterization 2DONG Energy and Inbicon Inaugurate One of the World's Largest Demo Plants for 2nd Generation Biofuel 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
(Date:12/3/2014)... Calif. , Dec. 2, 2014   ... globally deployed, innovative test solutions for military, aerospace, ... newest version of its successful TS-900 PXI ... performance and features of high-end systems to customers ... outstanding value compared to traditional ATE. ...
Breaking Biology News(10 mins):Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Harbor Laboratory (CSHL) have discovered how a protein long ... actually triggers this process in cells. The ... enzyme that attaches phosphate molecules to other proteins to ... DDK performs this operation, called phosphorylation, on a protein ...
... in Montreal, made this discovery Montral, January ... researcher at the Institut de recherches cliniques de Montral (IRCM), ... of visual nerves towards the brain. Their findings have been ... Neuroscience . The research was conducted in collaboration with Dr. ...
... traps deep in the Sumatran jungle have captured first-time images ... unique insight into the elusive tiger,s behaviour. After a ... researchers seeking to record tigers in the Sumatran jungle caught ... stopped to sniff and check out the camera trap. ...
Cached Biology News:CSHL scientists uncover role of protein critical for activating DNA replication 2Discovery of a new molecular mechanism that guides visual nerves towards the brain 2Camera traps yield first-time film of tigress and cubs 2Camera traps yield first-time film of tigress and cubs 3
... formulated specifically for Alkaline Phosphatase conjugates. ... activity for both the enzyme and the ... This product has been chemically engineered ... a longer shelf life, resistance to various ...
... The PATH™ Protein Microarray Slide features ... immunoassays. The,PATH™ Slide is the first ... many benefits of nitrocellulose in a ... excellent signal-to-noise ratios. ,The PATH™ ...
... Cassettes facilitate the hybridization of DNA or ... 25mm x 75mm glass slides. The proprietary ... correct for poor flatness, as is often ... low volume chamber (67uL analytical cavity volume) ...
... Mouse monoclonal [3D12] to Lambda Free ... Mixture of light chains of human ... for independent constantly expressed epitope of ... dimer forms of free lambda chains ...
Biology Products: